Dillon Valdez
Growth Investor, Public Portfolio Journal
Rocket Lab's delayed Neutron first flight pushes out a key part of its planned launch capacity. Flight one has moved to 2027, at least 1.5 years later than the previously indicated timing; the lack of clearer guidance is frustrating. The stock could fall 50% if it breaks key support, though that downside is conditional. x.com x.com x.comÂ
Rocket Lab is a bet on Peter Beck turning it into an end-to-end space infrastructure company, making space a repeatable operating business. Electron and HASTE provide launch cadence, Space Systems builds spacecraft and components, and Neutron adds larger reusable capacity, since customers need launch, integration and hardware from one stack. Q1 2026 revenue rose 63.5% to $200.3M, backlog topped $2.2B, and it signed 31 Electron/HASTE and 5 Neutron launches, more launches than in all of 2025. x.comÂ
Repeated Neutron delays undermine the premium on Rocket Lab stock when execution keeps slipping. The company does not live or die by Neutron, but 50x sales was unjustified; even at 26x 2027 sales, a legitimate price suggests another 50% decline. x.com x.comÂ
Rocket Lab's only 'moat' was Neutron, and its reported launch delay now amounts to cancellation for the investment case. The quoted report puts its inaugural launch in 2027; $2.99 is floated as a possible share price. x.comÂ
Rocket Lab's Neutron delay looks like a manufacturing issue, not a flawed design. Rocket Lab says it identified and mitigated dome voids, but this second setback delays launch revenue; first flight could slip to mid-2027 or later if testing finds more issues. Space Systems is about 81% of revenue and backlog is around $2.4B, sustaining the business as Neutron develops. Rocket Lab could still become a megacap over the next decade. x.comÂ
Rocket Lab's Neutron delay could drag public space stocks down because the space basket usually trades together. Rocket Lab is likely to pull AST SpaceMobile down with it, especially in a bad market. The delay also pushes back a possible AST launch on Neutron, though that launch was not expected and the news is not necessarily bad for AST directly. x.com x.com x.comÂ
Rocket Lab shares look set to grind as Neutron's first flight slips, even though the core business is at its strongest. Q2 revenue hit a record $234.1M, up 62%, and backlog rose 137% to $2.356B. But the Q3 guide cuts GAAP gross margin to 29-31% from 36.1%, below the ~37.6% expected, with adjusted EBITDA losses widening to $17-23M on low-margin satellite programs, Mynaric integration and Neutron spending. A Q1 2027 Neutron debut is now the base case, which will disappoint high expectations. x.comÂ
Rocket Lab's Neutron delay looks minor because its cadence should scale much faster than Terran-R's in the long run, even if Terran-R flies first. A forward-dome manufacturing issue moved Neutron's first flight to 2027; Q2 now sounds more likely than the expected Q1. The delay is disappointing, but Electron reached 100 launches faster than Falcon 9, and Iridium does not need Neutron soon. Peter Beck's transparency is appreciated; management may have waited for a solution despite bad timing. … Show more
Rocket Lab has no reason to climb back above $100 anytime soon without a huge catalyst. Earnings were OK but nothing to rave about, and Neutron was delayed. x.comÂ
Rocket Lab's government awards and backlog look priced in, while the costs of Neutron do not. Its space-beta monopoly has ended with SpaceX's listing, and it needs to max out R&D to accelerate Neutron before its maiden flight. A brand-new rocket, a new methalox engine and a new launch site burning more money mean weak earnings the market has apparently not priced. x.com x.comÂ
Rocket Lab's existing Space Systems business makes Neutron upside optionality rather than the whole investment case. Space Systems supplied $189.5M, about 81% of Q2's record $234M revenue, alongside Electron launches, defense work, satellite manufacturing and components. Delaying Neutron's first launch to 2027 hurts a major catalyst and raises execution questions, but rushing a rocket failure would be costlier. x.comÂ
Rocket Lab could face a difficult 9-12 months because much of the space industry's future is already priced into equity valuations, even as its business and backlog grow. A monthly close below the $61 21-month EMA would raise the risk that the uptrend has ended and shift attention toward $35-45 for a better long-term entry; holding $61 preserves a more constructive reading. The company could still trade considerably higher over a longer horizon. x.comÂ
